Fig 1.
Study search and selection flow diagram.
Table 1.
Characteristics of the 12 included RCTs.
Fig 2.
Forest plot of meta-analysis for hazard ratios comparing (A) OS, (B) PFS, and (C) ORR in patients who received ICIs plus chemotherapy versus chemotherapy.
Fig 3.
Forest plot of meta-analysis of immune-related adverse events with ICIs plus chemotherapy versus chemotherapy.
(A) grade 1–2 treatment-related adverse events, (B) grade 3–5 treatment-related adverse event.
Table 2.
Subgroup analysis of OS, PFS of ICIs plus chemotherapy vs chemotherapy in NSCLC.
Table 3.
Subgroup analysis of ORR of ICIs plus chemotherapy in NSCLC.